Uma Valeti
University of Minnesota
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Uma Valeti.
Journal of the American College of Cardiology | 2011
James A. Goldstein; Kavitha Chinnaiyan; Aiden Abidov; Stephan Achenbach; Daniel S. Berman; Sean W. Hayes; Udo Hoffmann; John R. Lesser; Issam Mikati; Brian J. O'Neil; Leslee J. Shaw; Michael Y H Shen; Uma Valeti; Gilbert Raff
OBJECTIVES The purpose of this study was to compare the efficiency, cost, and safety of a diagnostic strategy employing early coronary computed tomographic angiography (CCTA) to a strategy employing rest-stress myocardial perfusion imaging (MPI) in the evaluation of acute low-risk chest pain. BACKGROUND In the United States, >8 million patients require emergency department evaluation for acute chest pain annually at an estimated diagnostic cost of >
Journal of the American Heart Association | 2015
Erik B. Schelbert; Kayla Piehler; Karolina M. Zareba; James C. Moon; Martin Ugander; Daniel Messroghli; Uma Valeti; Chung Chou H. Chang; Sanjeev G. Shroff; Javier Díez; Christopher A Miller; Matthias Schmitt; Peter Kellman; Javed Butler; Mihai Gheorghiade; Timothy C. Wong
10 billion. METHODS This multicenter, randomized clinical trial in 16 emergency departments ran between June 2007 and November 2008. Patients were randomly allocated to CCTA (n = 361) or MPI (n = 338) as the index noninvasive test. The primary outcome was time to diagnosis; the secondary outcomes were emergency department costs of care and safety, defined as freedom from major adverse cardiac events in patients with normal index tests, including 6-month follow-up. RESULTS The CCTA resulted in a 54% reduction in time to diagnosis compared with MPI (median 2.9 h [25th to 75th percentile: 2.1 to 4.0 h] vs. 6.3 h [25th to 75th percentile: 4.2 to 19.0 h], p < 0.0001). Costs of care were 38% lower compared with standard (median
Journal of the American Heart Association | 2013
Timothy C. Wong; Kayla Piehler; Karolina M. Zareba; Kathie Lin; Ashley Phrampus; Agam Patel; James C. Moon; Martin Ugander; Uma Valeti; Jonathan E. Holtz; Bo Fu; Chung-Chou H. Chang; Michael A. Mathier; Peter Kellman; Javed Butler; Mihai Gheorghiade; Erik B. Schelbert
2,137 [25th to 75th percentile:
Springer US | 2012
Uma Valeti; Robert F. Wilson; Zeev Vlodaver
1,660 to
Texas Heart Institute Journal | 2014
Prabhjot S. Nijjar; Sofia Carolina Masri; Ashenafi Tamene; Helina Kassahun; K. Liao; Uma Valeti
3,077] vs.
European Heart Journal | 2016
Prabhjot S. Nijjar; Fahad Iqbal; M. Chadi Alraies; Uma Valeti; S. Murthy Tadavarthy
3,458 [25th to 75th percentile:
Journal of Cardiovascular Magnetic Resonance | 2015
Yaron Fridman; Timothy C. Wong; Kayla Piehler; Karolina M. Zareba; James C. Moon; Martin Ugander; Daniel Messroghli; John M. Jakicic; Uma Valeti; Chung Chou Chang; Sanjeev G. Shroff; Christopher A Miller; Matthias Schmitt; Peter Kellman; Javed Butler; Mihai Gheorghiade; Erik B. Schelbert
2,900 to
Journal of Cardiovascular Magnetic Resonance | 2014
Timothy C. Wong; Gaby Captur; Uma Valeti; James C. Moon; Erik B. Schelbert
4,297], p < 0.0001). The diagnostic strategies had no difference in major adverse cardiac events after normal index testing (0.8% in the CCTA arm vs. 0.4% in the MPI arm, p = 0.29). CONCLUSIONS In emergency department acute, low-risk chest pain patients, the use of CCTA results in more rapid and cost-efficient safe diagnosis than rest-stress MPI. Further studies comparing CCTA to other diagnostic strategies are needed to optimize evaluation of specific patient subsets. (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment [CT-STAT]; NCT00468325).
Journal of Cardiovascular Magnetic Resonance | 2014
Hareeprasad R Vongooru; Ashenafi Tamene; Prabhjot S. Nijjar; Sue Duval; Uma Valeti
Background Myocardial fibrosis (MF) in noninfarcted myocardium may be an interstitial disease pathway that confers vulnerability to hospitalization for heart failure, death, or both across the spectrum of heart failure and ejection fraction. Hospitalization for heart failure is an epidemic that is difficult to predict and prevent and requires potential therapeutic targets associated with outcomes. Method and Results We quantified MF with cardiovascular magnetic resonance extracellular volume fraction (ECV) measures in 1172 consecutive patients without amyloidosis or hypertrophic or stress cardiomyopathy and assessed associations with outcomes using Cox regression. ECV ranged from 16.6% to 47.8%. Over a median of 1.7 years, 111 patients experienced events after cardiovascular magnetic resonance, 55 had hospitalization for heart failure events, and there were 74 deaths. ECV was more strongly associated with outcomes than “nonischemic” MF observed with late gadolinium enhancement, thus ECV quantified MF in multivariable models. Adjusting for age, sex, renal function, myocardial infarction size, ejection fraction, hospitalization status, and heart failure stage, higher ECV was associated with hospitalization for heart failure (hazard ratio 1.77; 95% CI 1.32 to 2.36 for every 5% increase in ECV), death (hazard ratio 1.87 95% CI 1.45 to 2.40) or both (hazard ratio 1.85, 95% CI 1.50 to 2.27). ECV improved classification of persons at risk and improved model discrimination for outcomes (eg, hospitalization for heart failure: continuous net reclassification improvement 0.33, 95% CI 0.05 to 0.66; P=0.02; 0.16, 95% CI 0.01 to 0.33; P=0.02; integrated discrimination improvement 0.037, 95% CI 0.008 to 0.073; P<0.01). Conclusion MF measured by ECV is associated with hospitalization for heart failure, death, or both. MF may represent a principal phenotype of cardiac vulnerability that improves risk stratification. Because MF can be reversible, cells and enzymes regulating collagen could be potential therapeutic targets.
Journal of Cardiovascular Magnetic Resonance | 2013
Ian C Chang; Helina Kassahun; Uma Valeti
Background Hospitalization for heart failure (HHF) is among the most important problems confronting medicine. Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) robustly identifies intrinsic myocardial damage. LGE may indicate inherent vulnerability to HHF, regardless of etiology, across the spectrum of heart failure stage or left ventricular ejection fraction (LVEF). Methods and Results We enrolled 1068 consecutive patients referred for CMR where 448 (42%) exhibited LGE. After a median of 1.4 years (Q1 to Q3: 0.9 to 2.0 years), 57 HHF events occurred, 15 deaths followed HHF, and 43 deaths occurred without antecedent HHF (58 total deaths). Using multivariable Cox regression adjusting for LVEF, heart failure stage, and other covariates, LGE was associated with first HHF after CMR (HR: 2.70, 95% CI: 1.32 to 5.50), death (HR: 2.13, 95% CI: 1.08 to 4.21), or either death or HHF (HR: 2.52, 95% CI: 1.49 to 4.25). Quantifying LGE extent yielded similar results; more LGE equated higher risks. LGE improved model discrimination (IDI: 0.016, 95% CI: 0.005 to 0.028, P=0.002) and reclassification of individuals at risk (continuous NRI: 0.40, 95% CI: 0.05 to 0.70, P=0.024). Adjustment for competing risks of death that shares common risk factors with HHF strengthened the LGE and HHF association (HR: 4.85, 95% CI: 1.40 to 16.9). Conclusions The presence and extent of LGE is associated with vulnerability for HHF, including higher risks of HHF across the spectrum of heart failure stage and LVEF. Even when LVEF is severely decreased, those without LGE appear to fare reasonably well. LGE may enhance risk stratification for HHF and may enhance both clinical and research efforts to reduce HHF through targeted treatment.